Effects of sacubitril/valsartan on renal function in patients with primary hypertension
- VernacularTitle:沙库巴曲缬沙坦对原发性高血压患者肾功能的影响
- Author:
Yajun XIE
1
;
Bei ZHAO
2
;
Xueyao FENG
2
;
Shixing LI
3
;
Xiaoye LI
1
;
Ning SHI
1
Author Information
1. Dept. of Pharmacy，PLA Strategic Support Force Characteristic Medical Center，Beijing 100101，China
2. Dept. of Cardiology，PLA Strategic Support Force Characteristic Medical Center，Beijing 100101，China
3. Dept. of Cardiology，First Medical Center of the Cardiovascular Medicine Department Stationed at the Chinese PLA General Hospital，Beijing 100853，China
- Publication Type:Journal Article
- Keywords:
sacubitril/valsartan;
primary hypertension;
renal function;
serum creatinine;
serum potassium;
eGFR
- From:
China Pharmacy
2024;35(14):1770-1775
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To investigate the effects of sacubitril/valsartan on renal function in patients with primary hypertension. METHODS A retrospective study was conducted among patients with primary hypertension who were admitted to PLA Strategic Support Force Characteristic Medical Center from January 2018 to June 2023. Based on their medication， they were divided into two groups： sacubitril/valsartan group and valsartan group. Propensity score matching was used to match baseline data between the two groups. Patients were treated with antihypertensive drugs based on improving their lifestyle. Sacubitril/valsartan group additionally received oral administration of 200 mg Sacubitril/valsartan tablets once daily， while valsartan group additionally received oral administration of 80 mg Valsartan capsules once daily. The increase amplitude of serum creatinine from baseline， the proportion of patients with elevated serum creatinine ＞30%-50% or ＞50%， and the proportion of patients with hyperkalemia （serum potassium ≥5.5 mmol/L） were compared between two groups at 2 months and 6 months after treatment. The trends of changes in serum creatinine， serum potassium and estimated glomerular filtration rate （eGFR） were compared between the two groups before treatment （at baseline）， 2 months and 6 months after treatment. RESULTS After propensity score matching， there were 62 patients in sacubitril/valsartan group and 61 patients in valsartan group； there were no significant differences in baseline characteristics between the two groups before treatment （P＞0.05）， indicating comparability. After 6 months of treatment， the increase of serum creatinine in the sacubitril/valsartan group was significantly lower than that in the valsartan group （P＝0.003）； the proportion of patients with elevated serum creatinine ＞30%-50% in the sacubitril/valsartan group was significantly lower than that in the valsartan group （P＝0.045）. None of the patients experienced hyperkalemia events after 2 months and 6 months of treatment. Repeated measures analysis of variance showed significantly statistical differences in serum creatinine and eGFR between the two groups within 6 months of treatment （P＜0.001）. Patients taking valsartan experienced a continuous increase in serum creatinine levels and a decrease in eGFR， while patients taking sacubitril/valsartan showed a first increase and then a decrease in serum creatinine levels， and a first decrease and then an increase in eGFR with a prolonged duration of medication. CONCLUSIONS Sacubitril/valsartan can delay or even reverse the decline in renal function levels， and limit the deterioration of renal function in patients with primary hypertension， without increasing the risk of hyperkalemia.
